報價延遲最少15分鐘:2026/08/02 11:05 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3446 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.35/-0.75
|
|
企業價值
1.35M
|
| 資產負債 |
|
每股賬面淨值
-0.31
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
131.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques. |
